Skin Changes With IBD: Erythema Nodosum, Pyoderma, Drug Reactions

Skin changes with IBD are common enough that dermatologic problems rank among the most frequent complications occurring outside the digestive tract. A systematic review and meta-analysis found that extraintestinal manifestations affect about 24% of people with inflammatory bowel disease overall, and cutaneous involvement occurs in up to 15% of patients. For someone with Crohn's disease or ulcerative colitis, a new rash, bump, or sore can be hard to interpret. Some skin changes track closely with gut inflammation, some behave on their own timeline, and some come from the medications used to treat the disease. Learning to tell these categories apart, and recording what you see, gives your gastroenterologist and dermatologist the context they need to respond correctly.

Erythema Nodosum: Tender Red Bumps That Track Your Gut

Erythema nodosum is the most common skin manifestation of IBD. It shows up as tender, raised nodules, and the Crohn's & Colitis Foundation describes these tender red nodules as usually appearing on the shins or ankles, sometimes on the arms. The lumps are often warm and painful to touch, and they may turn purplish over several days before fading like a deep bruise. Johns Hopkins Medicine notes that erythema nodosum often resolves on its own within about six weeks.

What makes erythema nodosum useful as a signal is its timing. It is a self-limited condition that coincides with intestinal IBD activity and improves with IBD treatment, and the Foundation notes it generally appears in conjunction with a flare, or sometimes just before one. It is also more frequent in Crohn's disease than in ulcerative colitis and is more common in women. Because the nodules parallel bowel inflammation, controlling the underlying disease is usually what settles them, and specific skin treatment beyond pain relief is often unnecessary.

Pyoderma Gangrenosum: An Ulcer That Needs Prompt, Gentle Care

Pyoderma gangrenosum is less common than erythema nodosum, occurring in roughly 0.5% to 2.6% of people with IBD, but it is more serious. It begins as small blisters that join together to form deep, chronic ulcers, most often on the shins or ankles. The ulcers can enlarge quickly and are painful, and they are frequently mistaken for a skin infection. Unlike erythema nodosum, it is unclear whether pyoderma gangrenosum runs parallel to bowel disease activity, so the skin lesion can flare even when the gut feels controlled.

One feature of pyoderma gangrenosum makes prompt, correct care essential. The lesion shows pathergy, meaning it arises or worsens at sites of trauma. For that reason surgical debridement can backfire: pyoderma gangrenosum is known to worsen following surgical debridement due to pathergy, and the condition is easily misdiagnosed as necrotizing fasciitis or another infection, misdirecting a surgeon toward aggressive debridement with serious consequences. If you have a rapidly growing, painful ulcer, treat it as urgent and ask that a dermatologist or your gastroenterologist review it before anyone cuts or debrides it. Standard treatment leans on immune-directed therapy rather than surgery, with systemic corticosteroids and cyclosporine as first-line options and biologics such as anti-TNF agents used in more resistant cases. Wounds should be handled gently, cleaned with lukewarm sterile saline or a mild disinfectant rather than scrubbed.

When Skin Changes Come From Your Medication

Not every rash reflects the disease itself. Some skin problems from IBD medication are reactions to the treatment. The clearest example is paradoxical psoriasis, a psoriasis-like eruption that can develop during anti-TNF therapy even though these same drugs are used to treat psoriasis. It occurs in about 2% to 5% of patients treated with anti-TNF drugs, with a slight tendency toward women. The most common patterns are palmoplantar pustular eruptions and plaque-type or guttate psoriasis, with nail and scalp involvement also described. This matters because the appearance can overlap with disease-related rashes, and the right response, whether to add topical treatment, adjust the dose, or switch to a different class of biologic, depends on recognizing the medication link.

Other therapies carry their own dermatologic considerations, from injection-site reactions to increased sensitivity that comes with immune suppression. The practical takeaway is that timing relative to starting or changing a drug is one of the most valuable clues. A rash that begins weeks after a new injection tells a different story than nodules that flare alongside abdominal symptoms.

What to Document for Your Care Team

Because these categories look similar to an untrained eye and often present on the legs, a documented record turns a confusing rash into reviewable evidence. Photographs taken in consistent lighting, dated, and including something for scale help a clinician judge whether a lesion is growing or healing. Alongside images, a short written log is worth keeping.

The most useful details to record are:

• Location, size, color, and whether the area is a bump, blister, or open ulcer, plus how it has changed over days
• Timing relative to your gut symptoms and any recent flare
• Timing relative to starting, stopping, or changing a medication

This information lets your gastroenterologist and dermatologist work from the same picture. It helps them separate erythema nodosum that tracks a flare from a medication reaction, and it flags an ulcer that could be pyoderma gangrenosum before anyone treats it as an ordinary wound.

Putting the Pieces Together

Skin changes with IBD fall into recognizable groups, and knowing the group shapes the response. Erythema nodosum usually mirrors bowel activity and settles as the disease is controlled. Pyoderma gangrenosum needs prompt evaluation and gentle care, because debridement can worsen it through pathergy. Medication reactions such as anti-TNF paradoxical psoriasis follow the treatment rather than the gut. None of these should be self-diagnosed from a single glance, and none replace an in-person evaluation. What you can do is observe carefully, photograph and date what you see, and note how each change lines up with your symptoms and your drug schedule, so the specialists reading your skin have the full timeline in front of them.